Delcath opens European headquarters in Ireland

Delcath Systems Inc., developer of the Hepatic CHEMOSAT® Delivery System for targeting liver cancer, has officially opened its European headquarters in Galway, Ireland.

The CHEMOSAT device delivers concentrated chemotherapy to the liver with manageable systemic toxicity. The company predicts that as many as 56,000 patients in Europe with cancers in the liver could benefit from this therapeutic treatment each year.

The opening of its headquarters follows the achievement of several European milestones for Delcath. The Company has established initial launch and training agreements with nine leading cancer treatment centres across Europe, and has recently received its first commercial orders for the system.

It also recently received CE Mark for the second generation hemofiltration cartridge contained in the device, which has demonstrated removal of chemotherapeutic agent (melphalan hydrochloride) of greater than 98 per cent during drug infusion in an in vivo study.


“Galway provides us with an excellent base from which we can continue our commercialisation of the CHEMOSAT system in Europe” said Eamonn P. Hobbs, President and CEO of Delcath System, Inc.

“This region is the European home for many international medical device and pharmaceutical companies, and we have been able to staff our headquarters with well-qualified, experienced personnel. Together with the assistance provided by IDA Ireland, the area was a natural choice.”

“I am very pleased to have been invited to open the new European headquarters for Delcath in Galway,” said Eamon Gilmore TD, Tánaiste (deputy Prime Minister) and Minister for Foreign Affairs and Trade of Ireland. “Delcath is a very welcome and important addition to the strong life sciences sector in Ireland. Delcath joins the growing number of companies who have recognised the depth of healthcare talent available in Ireland to support their plans for business expansion in Europe.”